Access cutting-edge stroke treatment through this clinical trial at a research site in Burlingame. Study-provided care at no cost to qualified participants.
Access stroke specialists in Burlingame at no cost
This study follows strict safety protocols and ethical guidelines
All study-related stroke treatment provided free
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m
Sponsor: Joseph Broderick, MD
Check if you qualify for this stroke clinical trial in Burlingame, CA
If you're searching for stroke treatment options in Burlingame, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Burlingame research site is actively enrolling participants for this clinical trial. You'll receive care from experienced stroke specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.